Prosecution Insights
Last updated: October 02, 2026
Application No. 18/703,100

SUBCUTANEOUS ABRASION TREATMENT FOR STRETCH MARKS

Non-Final OA §102§103
Filed
Apr 19, 2024
Priority
Oct 20, 2021 — provisional 63/257,881 +1 more
Examiner
GEIGER, RACHAEL L
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
The Children's Medical Center Corporation
OA Round
3 (Non-Final)
82%
Grant Probability
Favorable
3-4
OA Rounds
4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allowance Rate
102 granted / 124 resolved
+12.3% vs TC avg
Strong +18% interview lift
Without
With
+18.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
29 currently pending
Career history
158
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
49.3%
+9.3% vs TC avg
§102
36.8%
-3.2% vs TC avg
§112
10.8%
-29.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 124 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Drawings The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the rasps (especially with regard to Fig. 1G which disclose that the abrasive surface is an edge not a rasp) must be shown or the feature(s) canceled from the claim(s). No new matter should be entered. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 8/18/26 has been entered. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-2, 4-9, 16-19 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Weitzner et al. (US 2018/0206864 A1). Regarding claim 1, Weitzner discloses a subcutaneous abrasion device (Figs. 7A-7C) comprising: a handle (i.e., handle is located proximally of 215a but may include 215a); an elongated shaft 146a extending distally from the handle (i.e., Fig. 7C); and an abrasive surface (i.e., cutting portions of 146a) disposed on a distal end portion of the elongated shaft (Fig. 7C), wherein the abrasive surface has a width that is greater than a width of the elongated shaft (i.e., as shown in Fig. 7C), wherein the abrasive surface includes a projection (i.e., each of 146a) rigidly fixed to the elongated shaft (i.e., at least by way of 213), wherein the projection includes one or more edges (para. [0041]) extending radially outwards from the elongated shaft (Fig. 7C), wherein the one or more edges extend between a first proximal location (i.e., at 215a) and a second distal location (i.e., at 213) along a length of the elongated shaft (Fig. 7C), and wherein the one or more edges is configured to subcutaneously abrade an inner surface of a dermis of a subject (i.e., by removing the necrotic pocket as disclosed in para. [0041]) without substantially cutting or puncturing the dermis of the subject (i.e., at least since the atraumatic tip 213 protects the tissue wall). Regarding claim 2, Weitzner discloses the subcutaneous abrasion device of claim 1. Weitzer doesn’t directly disclose wherein the inner surface of the dermis includes a portion of a reticular layer of the dermis of the subject. The limitation “wherein the inner surface of the dermis includes a portion of a reticular layer of the dermis of the subject” is being interpreted as an intended use limitation. As seen in MPEP section 2114 section 2, a claim containing a "recitation with respect to the manner in which a claimed apparatus is intended to be employed does not differentiate the claimed apparatus from a prior art apparatus" if the prior art apparatus teaches all the structural limitations of the claim. Ex parte Masham, 2 USPQ2d 1647. Thus, it’s seen if the prior art has the claimed structure of the invention, it is able to perform the function. As seen here, the device can be positioned such that the head 213 is butted up against the reticular layer of the dermis to protect that layer while the edge cuts the necrotized pocked as disclosed in para. [0041]. Therefore, since the structure of the device protects layers of tissue, the function is met. Regarding claim 4, Weitzner discloses the subcutaneous abrasion device of claim 1. Weitzer also discloses wherein the abrasive surface includes a head portion (i.e., as indicated along the arrow shown in Fig. 7B) that is wider than the elongated shaft (Figs. 7B-7C). Regarding claim 5, Weitzner discloses the subcutaneous abrasion device of claim 1. Weitzer also discloses wherein the abrasive surface includes a deployable head that deploys from a first undeployed configuration to a second deployed configuration (Figs. 7B-7C). Regarding claim 6, Weitzner discloses the subcutaneous abrasion device of claim 5. Weitzer also discloses wherein the deployable head is selectively deployable within a subject (para. [0041]). Regarding claim 7, Weitzner discloses the subcutaneous abrasion device of claim 1. Weitzer also discloses wherein the elongated shaft is configured to have an adjustable length (Figs. 7A-7C). Regarding claim 8, Weitzner discloses the subcutaneous abrasion device of claim 1. Weitzer also discloses wherein the elongated shaft is a telescoping elongated shaft (Figs. 7A-7C). Regarding claim 9, Weitzner discloses the subcutaneous abrasion device of claim 1. Weitzer also discloses wherein at least the abrasive surface is configured to be inserted into an opening in the subject (para. [0041]). Regarding claim 16, Weitzner discloses the subcutaneous abrasion device of claim 1. Weitzer also discloses wherein the abrasive surface is in a fixed configuration on the distal end portion of the elongated shaft (Fig. 7C). Regarding claim 17, Weitzner discloses the subcutaneous abrasion device of claim 1. Weitzer also discloses wherein the elongated shaft and abrasive surface are configured to be inserted through an opening formed in a skin of the subject (para. [0041]). Regarding claim 18, Weitzner discloses a subcutaneous abrasion device (Figs. 7A-7C) comprising: a handle (i.e., proximal to 215a but may also include 215a); an elongated shaft 149 extending from the handle (Fig. 7C), the elongated shaft having a length extending from a proximal end of the elongated shaft adjacent to the handle to a distal tip of the elongated shaft distal from the handle (Fig. 7C); and an abrasive surface (i.e., cutting surface of 146a) disposed along the length of the elongated shaft between the proximal end and the distal tip (Fig 7C), wherein the abrasive surface has a width that is greater than a width of the elongated shaft (Fig. 7C), wherein the abrasive surface includes a projection rigidly fixed to the elongated shaft (i.e., each of 146a are projections and fixed by way of 213), wherein the projection includes one or more edges extending outwards from the elongated shaft (para. [0041]), and wherein the one or more edges are configured to subcutaneously abrade an inner surface of a dermis of a subject without substantially cutting or puncturing the dermis of the subject (para. [0041] at least to cut necrotic tissue without cutting or puncturing the tissue wall by use of 213). Regarding claim 19, Weitzner discloses the subcutaneous abrasion device of claim 18. Weitzer also discloses wherein the one or more edges extend between a first proximal location (Fig.7A) and a second distal location along the length of the elongated shaft (Fig. 7C) between the proximal end and the distal tip of the elongated shaft (Fig. 7C). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 3 is rejected under 35 U.S.C. 103 as being unpatentable over Weitzer in view of Bleich et al. (20140163562) Regarding claim 3, Weitzer discloses the subcutaneous abrasion device of claim 1. Weitzer doesn’t directly disclose wherein the abrasive surface includes one or more rasps. In the same field of endeavor of flexible tissue rasps, Bleich et al discloses wherein the abrasive surface includes one or more rasps (para. [0100]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the abrasive surface of Weitzer to have one or more rasps as disclosed by Bleich for purposes of providing an abrasive surface on one side of an element without causing damage to nearby non-target tissues as the body is translated (para. [0103]). Response to Arguments Applicant’s arguments with respect to claim(s) 1-9, 16-19 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to RACHAEL LYNN GEIGER whose telephone number is (571)272-6196. The examiner can normally be reached Mon-Fri 8:00am-5:00pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Darwin Erezo can be reached at 5712724695. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RACHAEL L GEIGER/ Examiner, Art Unit 3771 /BROOKE LABRANCHE/ Primary Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Show 5 earlier events
Apr 07, 2026
Response Filed
Apr 21, 2026
Final Rejection mailed — §102, §103
Jul 17, 2026
Applicant Interview (Telephonic)
Jul 17, 2026
Examiner Interview Summary
Aug 18, 2026
Request for Continued Examination
Aug 19, 2026
Response after Non-Final Action
Aug 25, 2026
Non-Final Rejection mailed — §102, §103
Sep 24, 2026
Interview Requested

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746025
MEDICAL DEVICE HANDLE ASSEMBLIES AND METHODS OF USING THE SAME
2y 4m to grant Granted Sep 29, 2026
Patent 12714449
CONTROL OF IVL SYSTEMS, DEVICES AND METHODS THEREOF
1y 4m to grant Granted Aug 25, 2026
Patent 12708371
EMBOLIZATION DEVICE
4y 3m to grant Granted Aug 18, 2026
Patent 12702434
ENDOSCOPIC TREATMENT DEVICE
1y 11m to grant Granted Aug 11, 2026
Patent 12697114
Scaffold and Suture Anchoring Device
4y 4m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
82%
Grant Probability
99%
With Interview (+18.3%)
2y 9m (~4m remaining)
Median Time to Grant
High
PTA Risk
Based on 124 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month